[Ovarian epithelial dysplasia: myth or reality? Review].

Gynecol Obstet Fertil

Département de chirurgie, centre Jean-Perrin, rue Montalembert, 63000 Clermont-Ferrand, France.

Published: November 2008

Ovarian epithelial dysplasia has been described in the ovarian surface epithelium by histologic, morphometric and nuclear profile studies. It could represent a potential precursor of ovarian malignancy in patients with genetic risk of ovarian cancer, although its natural history and progression to carcinoma are unpredictable. Diagnosis and identification of ovarian dysplasia would certainly be useful to understand the early steps of ovarian carcinogenesis. However, dysplasia in relation with ovulation induction seems to have a different pattern. We report dysplasia definitions and the current clinical management.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gyobfe.2008.05.003DOI Listing

Publication Analysis

Top Keywords

epithelial dysplasia
8
ovarian
6
dysplasia
5
[ovarian epithelial
4
dysplasia myth
4
myth reality?
4
reality? review]
4
review] ovarian
4
ovarian epithelial
4
dysplasia described
4

Similar Publications

Background The incidence of margin re-excision following breast conserving surgery (BCS) is a quality measure in the National Health Service. The threshold is less than 20% of all BCS procedures. Despite three decades of studies and a wealth of literature identifying multiple factors associated with increased risk for margin involvement, an accepted threshold rate affecting one in five procedures remains high.

View Article and Find Full Text PDF

Malignant transformation is a rare complication of ovarian mature cystic teratoma that occurs in 1-3% of cases. We herein report a case of squamous cell carcinoma originating from mature cystic teratoma of the ovary diagnosed 10 years after initial tumor detection. A 69-year-old woman presented to the Department of Internal Medicine with a seven-month history of abdominal fullness.

View Article and Find Full Text PDF

Caspase-4 Has Potential Utility as a Colorectal Tissue Biomarker for Dysplasia and Early-Stage Cancer.

Gastro Hep Adv

September 2024

School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.

Background And Aims: Colorectal cancer (CRC) is the second most deadly cancer globally. The rapidly rising incidence rate of CRC, coupled with increased diagnoses in individuals <50 years, indicates that early detection of CRC, and those at an increased risk of CRC development, is paramount to improve the survival rates of these patients. Here, we profile caspase-4 expression across 2 distinct CRC development pathways, sporadic CRC (sCRC) and inflammatory bowel disease-associated CRC (IBD-CRC), to examine its utility as a novel biomarker for CRC risk and diagnosis.

View Article and Find Full Text PDF

Objective: This study was aimed at investigating the roles of podoplanin (PDPN) as a marker associated with malignant development, progression, and poor prognosis in oral leukoplakia and various forms of oral squamous cell carcinoma (OSCC), particularly in relation to the extent of invasion.

Methods: Immunohistochemical analysis of PDPN was conducted on 77 histologically confirmed, formalin-fixed, paraffin-embedded samples representing various degrees of OSCC invasion and dysplasia grades.

Results: The samples were analyzed with Fisher's exact test and the Kruskal-Wallis test.

View Article and Find Full Text PDF

Background: Sunitinib resistance is a major challenge in advanced renal cell carcinoma (RCC). Clinically, elucidating the underlying mechanisms and developing practical countermeasures for sunitinib resistance in RCC is desirable. In previous studies, we found that circAGAP1 expression was significantly upregulated in clear cell RCC (ccRCC) and was strongly associated with poor prognosis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!